Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b and to Evaluate the Efficacy and Safety of Intratumoral Talimogene Laherparepvec in Combination With Systemic Pembrolizumab to Treat Subjects With Advanced Solid Tumors in Phase 2 (MASTERKEY-318)

Next Previous
Trial Profile

A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b and to Evaluate the Efficacy and Safety of Intratumoral Talimogene Laherparepvec in Combination With Systemic Pembrolizumab to Treat Subjects With Advanced Solid Tumors in Phase 2 (MASTERKEY-318)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Talimogene laherparepvec (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Basal cell cancer; Colorectal cancer; Gastric cancer; HER2 negative breast cancer; Liver cancer; Liver metastases; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Skin cancer; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MASTERKEY-318
  • Sponsors Amgen

    • Most Recent Events

    • 03 Sep 2023 This trial has been completed in belguim and Poland, according to European Clinical Trials Database record.
    • 11 Jul 2023 Status changed from active, no longer recruiting to completed.
    • 25 May 2023 Planned End Date changed from 26 Jul 2023 to 12 Jul 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top